SCHEMBL6180139

SCHEMBL6180139

Oc1nccc2cc3c(cc12)N(Cc1ccccc1)CC3

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR1A P08908 4/20 0.39
HTR1D P28221 4/20 0.39
HTR1B P28222 4/20 0.39
ACHE P22303 1/20 0.39
ALOX5 P09917 3/20 0.39
EPHX2 P34913 2/20 0.39
KMT2A Q03164 2/20 0.37
KDM4E B2RXH2 2/20 0.37
ALDH1A1 P00352 1/20 0.37
LMNA P02545 1/20 0.37
MAPT P10636 1/20 0.37
ROCK1 Q13464 1/20 0.36
ADRB2 P07550 1/20 0.36
ADRB1 P08588 1/20 0.36
ADRB3 P13945 1/20 0.36
GRM5 P41594 1/20 0.36
EGFR P00533 1/20 0.35
ERBB2 P04626 1/20 0.35
ERBB4 Q15303 1/20 0.35
DDB1 Q16531 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6180465 0.81 HTR1A (0.59) HTR1AHTR1DHTR1B
SCHEMBL6179764 0.80 HTR2C (0.51) HTR1AHTR1DHTR1B
SCHEMBL6179435 0.79 HTR1A (0.39) HTR1AHTR1DHTR1BACHEROCK1
SCHEMBL6179721 0.78 HTR6 (0.39) ACHEROCK1
SCHEMBL6179444 0.77 PTGDR2 (0.37) HTR1AHTR1DHTR1BACHEALOX5
SCHEMBL6179690 0.76 HTR1A (0.51) HTR1AHTR1DHTR1BACHE
SCHEMBL6180135 0.74 HTR1A (0.49) HTR1AHTR1DHTR1BACHE
SCHEMBL6179195 0.73 TP53 (0.44) ACHEKMT2AKDM4EALDH1A1LMNA
SCHEMBL8117765 0.72 ALK (0.43) HTR1AHTR1DHTR1BKDM4EALDH1A1
SCHEMBL16494456 0.72 ALOX5 (0.51) ACHEALOX5EPHX2KMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050239797-A1 Isoquinoline and quinazoline derivatives having a combined 5HT1A, 5HT1B, and 5HT1D receptor activity SMITHKLINE BEECHAM, PLC 2005-10-27 US disclosed
EP-1228043-B1 ISOQUINOLINE AND QUINAZOLINE DEIVATIVES HAVING A COMBINED 5HT1A, 5HT1B AND 5HT1D RECEPTOR ACTIVITY SMITHKLINE BEECHAM PLC (GB) 2005-01-12 EP disclosed
EP-1228043-A1 ISOQUINOLINE AND QUINAZOLINE DEIVATIVES HAVING A COMBINED 5HT1A, 5HT1B AND 5HT1D RECEPTOR ACTIVITY SMITHKLINE BEECHAM PLC (GB) 2002-08-07 EP disclosed
WO-2001032626-A1 ISOQUINOLINE AND QUINAZOLINE DERIVATIVES HAVING A COMBINED 5HT1A, 5HT1B AND 5HT1D RECEPTOR ACTIVITY SMITHKLINE BEECHAM P.L.C. (GB) 2001-05-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050239797-A1 Isoquinoline and quinazoline derivatives having a combined 5HT1A, 5HT1B, and 5HT1D receptor activity HTR1B, HTR1A, HTR1D HTR1A 2/4885HTR1D 3/4885HTR1B 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.